Semaglutide studies: 1,194 papers with results
Page 13 of 24
- Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.
Henney AE · Diabetes, obesity & metabolism · 2026
Observational study · 6 results
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
Rodriguez PJ · JAMA internal medicine · 2024
Observational study · 8 results
- Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity.
Chhabra KR · Obesity (Silver Spring, Md.) · 2026
Observational study · 7 results
- Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy.
Noreña JA · AACE endocrinology and diabetes · 2025
Observational study · 1 result
- Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD).
Michalak W · Journal of medical economics · 2025
Observational study · 3 results
- Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.
Stenberg E · Diabetes, obesity & metabolism · 2024
Observational study · 5 results
- Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.
Lunati ME · Pharmacological research · 2024
Observational study · 8 results
- Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.
Santos LB · Journal of clinical anesthesia · 2024
Observational study · 4 results
- Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy).
Reyes-Garcia R · Nutrients · 2025
Observational study · 12 results
- Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).
Caballero Mateos I · Nutrients · 2024
Observational study · 5 results
- Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X · Clinical drug investigation · 2024
Observational study · 10 results
- Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.
Rudofsky G · Advances in therapy · 2025
Observational study · 5 results
- Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).
Berra CC · Frontiers in endocrinology · 2022
Observational study · 9 results
- Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
Furusawa S · Endocrine journal · 2024
Observational study · 6 results
- Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation.
Li Y · Cardiovascular diabetology · 2024
Observational study · 4 results
- Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.
Toffoli B · International journal of molecular sciences · 2026
Observational study · 8 results
- Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.
Tan X · Advances in therapy · 2026
Observational study · 10 results
- Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?
Katzman J · Archives of orthopaedic and trauma surgery · 2026
Observational study · 4 results
- Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.
Kwon J · Expert review of endocrinology & metabolism · 2025
Observational study · 11 results
- Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.
Kakkar AK · Diabetes, obesity & metabolism · 2026
Observational study · 5 results
- Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.
Postema A · Diabetes, obesity & metabolism · 2026
Observational study · 6 results
- Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
Formichi C · Journal of endocrinological investigation · 2024
Observational study · 7 results
- Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study.
Díaz-Cerezo S · Patient preference and adherence · 2025
Observational study · 4 results
- Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.
Nersessian RSF · Anaesthesia · 2024
Observational study · 3 results
- Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Fadini GP · Diabetes, obesity & metabolism · 2024
Observational study · 6 results
- Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.
Buenaventura-Collazos DC · Frontiers in endocrinology · 2024
Observational study · 5 results
- Recurrent weight gain after sleeve gastrectomy: conversion to Roux-en-Y gastric bypass versus novel GLP-1 s.
Wasden K · Surgical endoscopy · 2025
Observational study · 6 results
- Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GLP-1/GIP RA) Exposures Presenting to the Emergency Department.
Gartner HT · The Annals of pharmacotherapy · 2025
Observational study · 14 results
- Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2).
Malighetti ME · Minerva endocrinology · 2026
Observational study · 11 results
- Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus.
Qaisar R · British journal of clinical pharmacology · 2026
Observational study · 9 results
- Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
Pérez-Belmonte LM · Frontiers in endocrinology · 2022
Observational study · 10 results
- Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study.
Nicolau J · Journal of addictive diseases · 2024
Observational study · 5 results
- Weighing your options-intragastric balloon versus semaglutide.
Choy K · Surgical endoscopy · 2024
Observational study · 4 results
- Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Savvidou S · Metabolic syndrome and related disorders · 2026
Observational study · 6 results
- Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study.
Cetiner S · BMC endocrine disorders · 2026
Observational study · 15 results
- Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.
Di Folco U · Acta diabetologica · 2022
Observational study · 14 results
- Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
Iwamoto H · Diabetes, obesity & metabolism · 2024
Observational study · 5 results
- Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes.
Omori Y · Journal of diabetes investigation · 2026
Observational study · 4 results
- Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
Hansen KB · Diabetic medicine : a journal of the British Diabetic Association · 2021
Observational study · 4 results
- Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
Arai T · Diabetes, obesity & metabolism · 2024
Observational study · 14 results
- Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study.
Bruno A · Aesthetic plastic surgery · 2026
Observational study · 7 results
- Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients.
El Khatib O · Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2026
Observational study · 20 results
- Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.
Al-Badri M · Journal of diabetes · 2025
Observational study · 16 results
- Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.
Nicolau J · Medicina clinica · 2026
Observational study · 10 results
- Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2024
Observational study · 16 results
- Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.
Jha AK · The Journal of the Association of Physicians of India · 2026
Observational study · 8 results
- Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.
Biasin M · Journal of cardiovascular medicine (Hagerstown, Md.) · 2026
Observational study · 11 results
- Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study.
Miertová Z · Scientific reports · 2026
Observational study · 8 results
- Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.
Okamoto A · Journal of diabetes and metabolic disorders · 2021
Observational study · 9 results
- Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.
Dăniluc L · Medicina (Kaunas, Lithuania) · 2025
Observational study · 2 results